•
Feb 28
AngioDynamics Q3 2025 Earnings Report
AngioDynamics reported strong Med Tech growth and improved margins in Q3 2025.
Key Takeaways
AngioDynamics posted $72M in revenue and narrowed its adjusted net loss, driven by double-digit Med Tech sales growth and improved gross margins. The company reported positive adjusted EBITDA and raised full-year guidance.
Med Tech segment grew 22.2%, driven by Auryon, AngioVac, AlphaVac, and NanoKnife.
Gross margin expanded to 54.0%, up 290 basis points YoY.
Adjusted EPS improved to $(0.08) from $(0.16) last year.
Received FDA clearance for NanoKnife System for prostate tissue ablation.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Forward Guidance
AngioDynamics increased its FY2025 guidance across all key metrics including revenue, Med Tech growth, gross margin, adjusted EBITDA, and adjusted EPS.
Positive Outlook
- Raised FY2025 net sales guidance to $285–$288M.
- Increased Med Tech growth expectation to 14–16%.
- Raised gross margin guidance to 53–54%.
- Adjusted EBITDA guidance increased to $4–$5M.
- Improved adjusted EPS guidance to $(0.31)–$(0.34).
Challenges Ahead
- Med Device sales expected to remain flat.
- Company continues to report operating losses.
- Free cash flow not specified, though cash burn occurred in Q3.
- Ongoing costs from manufacturing restructuring.
- Adjusted EPS remains in negative territory.
Revenue & Expenses
Visualization of income flow from segment revenue to net income